Skip to main content
Log in

The contribution of the measurement of seizure severity to quality of life research

  • Published:
Quality of Life Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy.Epilepsia 1979;20: 729–737.

    PubMed  Google Scholar 

  2. Rimmer EM, Richens A. Clinical pharmacology and medical treatment. In: Laidlaw J, Richens A, Oxley J, eds.A textbook of epilepsy, 3rd edn. Edinburgh: Churchill Livingstone, 1988: 421–483.

    Google Scholar 

  3. Porter RJ. Antiepileptic drugs: efficacy and inadequacy. In: Meldrum BS, Porter RJ, eds.New anti-convulsant drugs. Current problems in epilepsy, vol 4. London: John Libbey, 1986: 3–16.

    Google Scholar 

  4. Van Belle G, Temkin N. Design strategies in the clinical evaluation of new antiepileptic drugs. In: Pedley TA, Meldrum BS, eds.Recent advances in epilepsy,vol 1. Edinburgh: Churchill Livingstone, 1981: 93–111.

    Google Scholar 

  5. Rausch R, Crandall PH. Psychological status related to surgical control of temporal lobe seizures.Epilepsia 1982;23: 191–202.

    PubMed  Google Scholar 

  6. Vickrey BG, Hayes RD, Hermann BP, et al. Outcome with respect to quality of life. In: Engel J, ed.Surgical treatment of the epilepsies, 2nd edn. New York: Raven Press, 1993: 623–636.

    Google Scholar 

  7. Smith D, Baker G, Dewey M, et al. Seizure frequency, patient perceived seizure severity and the psychosocial consequences of intractable epilepsy.Epilepsy Res 1991;9: 231–241.

    PubMed  Google Scholar 

  8. Jacoby A, Johnson AL, Chadwick D. The psychosocial outcomes of antiepileptic drug withdrawal.Epilepsia 1992;33: 1123–1131.

    PubMed  Google Scholar 

  9. Baker GA, Smith DF, Dewey M, et al. The development of a seizure severity scale as an outcome measure in epilepsy.Epilepsy Res 1991;8: 245–251.

    PubMed  Google Scholar 

  10. Duncan JS, Sander JWAS. The Chalfont seizure severity scale.J Neurol Neurosurg Psychiat 1991;54: 873–876.

    PubMed  Google Scholar 

  11. Cramer JA, Smith DB, Mattson RH, et al. A method of quantification for the evaluation of antiepileptic drugs in adults.Neurology 1983;33: S26-S37.

    Google Scholar 

  12. Slevin MI, Plant H, Lynch D, et al. Who should measure quality of life, doctor or patient?.Br J Cancer 1987;57: 109–112.

    Google Scholar 

  13. Ziller RC. Self-other orientations and quality of life.Social Indicators Res 1974;1: 301–327.

    Google Scholar 

  14. Carmines EG, Zeller RA. Reliability and validity assessment. In: Sullivan J, ed.Quantitative applications in the social sciences. Newbury Park: Sage Publications, 1979.

    Google Scholar 

  15. Cronbach LJ. Coefficient alpha and the internal structure of tests.Psychometrika 1951;16: 297–334.

    Google Scholar 

  16. Commission on classification and terminology of the International League against Epilepsy. Proposal for revised clinical and electro-encephalographic classification of epileptic seizures.Epilepsia 1981;22: 489–501.

    Google Scholar 

  17. Smith D, Baker G, Davies G, et al.: Outcomes of add-on treatment with lamotrigine in partial epilepsy.Epilepsia 1993;34: 312–322.

    PubMed  Google Scholar 

  18. Baker GA, Smith D, Jacoby A,et al. Further development and testing of the Liverpool seizure severity scale. In preparation.

  19. Coatsworth JJ. Studies on the clinical efficacy of marketed antiepileptic drugs. NINDS Monograph No. 12. Washington, DC: US Government Printing Office, 1971.

    Google Scholar 

  20. Delgado-Escueta AV, Mattson RH, Smith DB, et al. Principles in designing clinical trials for antiepileptic drugs.Neurology 1983;33: S2-S7.

    Google Scholar 

  21. Mattson RH, Cramer JA, Delgado-Escueta AV, et al. A design for the prospective evaluation of the efficacy and toxicity of antiepileptic drugs.Neurology 1983;33: S14-S25.

    Google Scholar 

  22. Wijsman DJP, Hekster K, Keyser A, et al. Clinimetrics and epilepsy care.Pharm Weekblad (Sci) 1991;13: 182–188.

    Google Scholar 

  23. McNair DM, Lorr N, Droppleman LF.Manual for the Profile of Mood States. San Diego: Education and Industrial Testing Service, 1981.

    Google Scholar 

  24. Temkin RD, Wilensky AJ. New AEDs: are the compounds or the studies ineffective?Epilepsia 1986;27: 644–645.

    Google Scholar 

  25. Chadwick DW, Turnbull DM. The comparative efficacy of antiepileptic drugs for partial and tonic-clonic seizures.J Neurol Neurosurg Psychiat 1985;48: 1073–1077.

    PubMed  Google Scholar 

  26. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalised tonic-clonic seizures.N Engl J Med 1985;313: 145–151.

    PubMed  Google Scholar 

  27. Engel J. Outcome with respect to epileptic seizures. In: Engel J, ed.Surgical treatment of the epilepsies. New York: Raven Press, 1987: 553–571.

    Google Scholar 

  28. Hermann BP, Wyler AR, Ackerman B, Rosenthal T. Short-term psychological outcome of anterior temporal lobectomy.J Neurosurg 1989;71: 327–334.

    PubMed  Google Scholar 

  29. Glaser GH. Mechanisms of antiepileptic drug action: clinical indicators. In: Glaser GH, Penry JK, Woodbury DM, eds.Antiepileptic drugs: mechanisms of action. New York: Raven Press, 1980.

    Google Scholar 

  30. National Institutes for Health Concensus Conference. Surgery for epilepsy.JAMA 1990;264: 729.

    Google Scholar 

  31. Vickrey BG, Hays RD, Graber, J, et al. A health-related quality of life instrument for patients evaluated for epilepsy surgery.Med Care 1992;30: 299–319.

    PubMed  Google Scholar 

  32. Ware JE, Sherbourne CD. The MOS 36-item short-form health surgery (SF-36): Conceptual framework and item selection.Med Care 1992;30: 473–483.

    PubMed  Google Scholar 

  33. Thayer RE. Measurement of activation through selfreport.Psychol Reports 1967;20: 663–678.

    Google Scholar 

  34. Corney RH, Clare W. The construction, development and testing of a self-report questionnaire to identify social problems.Psychol Med 1985;15: 637–649.

    PubMed  Google Scholar 

  35. Hunt SM, McEwan J, McKenna SP. A quantitative approach to perceived health status: a validation study.J Epidemiol Comm Health 1980;34: 281–286.

    Google Scholar 

  36. Brown SW, Tomlinson LL. Anticonvulsant side effects: a self report questionnaire for use in community surveys.Br J Clin Pract 1984;18: S147-S149.

    Google Scholar 

  37. Zigmond AS, Snaith RP. The hospital anxiety and depression scale.Acta Psychiatrica 1983;67: 361–370.

    Google Scholar 

  38. Bradburn NM.The structure of psychological well-being. Chicago: Aldine, 1969.

    Google Scholar 

  39. Rosenberg M.Society and the adolescent self-image. Princeton, New Jersey: Princeton University Press, 1965.

    Google Scholar 

  40. Pearlin LI, Schooler C. The structure of coping.J Health Soc Behav 1978;19: 2–21.

    PubMed  Google Scholar 

  41. Binnie C. An overview: efficacy of lamotrigine. In: Richens A, ed.Clinical update on lamotrigine: a novel antiepileptic agent. Tunbridge Wells, Kent: Wells Medical Limited, 1992: 31–37.

    Google Scholar 

  42. Baker GA, Jacoby A, Dewey M,et al. Development of an instrument to assess quality of life in children with severe epilepsy and learning disability.Epilepsy Res: Submitted.

  43. Baker GA, Smith D. What patients think, feel and do, and how this relates to clinical trials. In: Brodie MJ, ed.Valproate: new milestones. London: Franklin Scientific Publications, 1992: 34–40.

    Google Scholar 

  44. Commission for the control of epilepsy and its consequences. Plan for nationwide action on epilepsy (DHEW Publication No. NIH78-276). Washington, DC: US Government Printing Office, 1978.

    Google Scholar 

  45. Arnston P, Droge D, Norton R, Murray E. The perceived psychosocial consequences of having epilepsy. In: Whitman S, Hermann B, eds.Psychopathology in epilepsy: social dimensions. New York: Oxford University Press, 1986: 143–161.

    Google Scholar 

  46. Levin R, Banks S, Berg B. Psychosocial dimensions of epilepsy: a review of the literature.Epilepsia 1988;29: 805–816.

    PubMed  Google Scholar 

  47. Baker GA, Smith DF, Dewey M, et al. The development, validity and reliability of a health-related quality of life model for epilepsy.Epilepsy Res 1993;16: 65–81.

    PubMed  Google Scholar 

  48. Jacoby A, Baker GA, Smith D, et al. Measuring the impact of epilepsy; the development of a novel scale.Epilepsy Res 1993;16: 83–88.

    PubMed  Google Scholar 

  49. Jacoby A. Quality of life and care in epilepsy. In: Chadwick DW, Baker GA, Jacoby A, eds.Quality of life and quality of care in epilepsy: update 1993. London: Royal Society of Medicine Services Limited, 1993: 66–78.

    Google Scholar 

  50. Baker GA, Jacoby A, Smith D, et al. The development of a novel scale to assess life fulfilment as part of the further refinement of a quality of life model for epilepsy.Epilepsia 1994;35: 591–596.

    PubMed  Google Scholar 

  51. Dodrill CB, Batzel L, Queisser HR, Temkin NR. An objective method for the assessment of psychological and social problems among epileptics.Epilepsia 1980;21: 123–135.

    PubMed  Google Scholar 

  52. Scambler G.epilepsy: the experience of illness. London: Tavistock and Routledge, 1989.

    Google Scholar 

  53. Jacoby A. Epilepsy and the quality of everyday life: Findings from a study of people with well-controlled epilepsy.Soc Sci Med 1992;34: 657–666.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smith, D., Baker, G.A., Jacoby, A. et al. The contribution of the measurement of seizure severity to quality of life research. Qual Life Res 4, 143–158 (1995). https://doi.org/10.1007/BF01833608

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01833608

Keywords

Navigation